Browsing Category

Supplier News

195 posts

The latest developments from suppliers of ingredients, development and manufacturing services, and related technologies for pharmaceutical and biopharmaceutical development and production.

Cambrex Expanding Small-Molecule API Capacity in US; Upgrading European Site
By

By
Claudio Russolo, Chief Operating Officer, Cambrex, a CDMO specializing in small-molecule development and manufacturing, outlined the company’s expansion plan at the DCAT Member Company Announcement Forum, held March 23, 2026,…

FUJIFILM Biotechnologies Provides Update on Multi-Year $8-Bn Expansion Plan
By

By
Maja Pedersen, Chief Operating Officer, FUJIFILM Biotechnologies, a CDMO of biologic drug substances, advanced therapies, and drug products, provided an update of the company’s multi-year $8-billion expansion plan at the…

Hovione Investing $100 M in US Expansion, Advancing Global Manufacturing Network
By

By
Hovione, a CDMO, is expanding its global manufacturing network with an investment cycle that includes an initial $100-million investment in the United States and additional capacity expansions across its European…

Made Scientific Expanding Cell-Therapy Mfg at New Jersey HQ Site
By

By
Syed T. Husain, Chairman & CEO, Made Scientific, a cell-therapy CDMO, outlined the company’s expansion plan at its headquarters site in New Jersey. The company is proceeding with a 12,000…

Samsung Biologics Adds US Biomanufacturing Capacity; Plans Expansion of Capacity for New Modalities; Partners with Lilly for Open Innovation Center 
By

By
Kevin Sharp, Executive Vice President and Head of Sales and Operations, Samsung Biologics, a CDMO of biologics and advanced therapies, outlined the company’s multi-faceted investment plan at the DCAT Member Company Announcement Forum, held March…

Siegfried Expanding Small-Molecule Drug-Substance Capacity Through Key Acquisitions  
By

By
Marcel Imwinkelried, CEO, Siegfried, a CDMO of drug substances and drug products, reported on key acquisitions by the company to increase its small-molecule drug-substance capacity in the US and Australia at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.   Siegfried announced…

Lonza Outlines Strategic Plan, Investments as Pure-Play CDMO 
By

By
Christian Seufert, Head of Advanced Synthesis, Lonza outlined the company’s strategic growth and investment plan at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week. The company is sharpening its…

Dottikon Provides Update on Multi-Year, $1-Billion Small-Molecule API Expansions 
By

By
Markus Blocher, CEO, Dottikon Exclusive Synthesis, a CDMO of intermediates, small-molecule active pharmaceutical ingredients (APIs) and high-performance chemicals, provided an update of a multi-year $1-billion investment plan at the DCAT Member Company Announcement Forum, held March…

Thermo Fisher Scientific Unveils $1-Billion CDMO Investment Plan 
By

By
At the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week, Jennifer Cannon, President of Commercial Operations for Thermo Fisher Scientific’s Pharma Services business, outlined the company’s global investment strategy aimed at expanding capacity, accelerating…

Vetter Outlines Major Expansion Plan for Commercial & Clinical Fill–Finish 
By

By
Lars Hahn, Senior Vice President, Global Sales Organization, Vetter Pharma International GmbH, a CDMO of drug product development, clinical, and commercial aseptic filling and packaging, outlined major expansions to increase the company’s…